Bifaceted functions of histone methyltransferases.

IF 3 4区医学 Q2 GENETICS & HEREDITY

Epigenomics Pub Date : 2025-07-13 DOI:10.1080/17501911.2025.2530925

Jawad Akhtar, Vassiliki Saloura

引用次数: 0

Abstract

In this perspective, Akhtar et al provide a brief overview of Enhancer of Zeste Homolog 2 (EZH2) and SET and MYND-domain containing 3 (SMYD3) as histone methyltransferases that function both as activators and repressors of gene transcription in cancer. The importance of deciphering the mechanisms underlying this bifaceted function toward thoughtful pharmacologic interventions is underlined and protein or mRNA degradation are highlighted as the most biologically rational pharmaceutical platforms to target these bifaceted histone methyltransferases.

查看原文本刊更多论文

组蛋白甲基转移酶的双面功能。

从这个角度来看，Akhtar等人简要概述了Zeste Homolog 2的增强子（EZH2）和SET和mynd结构域3 （SMYD3）作为组蛋白甲基转移酶，在癌症中作为基因转录的激活因子和抑制因子。研究人员强调了破译这种双面功能背后的机制对深思熟虑的药物干预的重要性，并强调了蛋白质或mRNA降解是针对这些双面组蛋白甲基转移酶的最生物学上合理的药物平台。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Epigenomics GENETICS & HEREDITY-

CiteScore

5.80

自引率

2.60%

发文量

审稿时长

>12 weeks

期刊介绍： Epigenomics provides the forum to address the rapidly progressing research developments in this ever-expanding field; to report on the major challenges ahead and critical advances that are propelling the science forward. The journal delivers this information in concise, at-a-glance article formats – invaluable to a time constrained community. Substantial developments in our current knowledge and understanding of genomics and epigenetics are constantly being made, yet this field is still in its infancy. Epigenomics provides a critical overview of the latest and most significant advances as they unfold and explores their potential application in the clinical setting.